Difference between revisions of "Dinaciclib (SCH-727965)"
Jump to navigation
Jump to search
(Created page with "==Mechanism of action== A cyclin dependent kinase inhibitor that selectively inhibits cyclin dependent kinases CDK1, CDK2, CDK5, and CDK9. ==Preliminary data== ===[[Multiple...") |
|||
| Line 3: | Line 3: | ||
==Preliminary data== | ==Preliminary data== | ||
| + | |||
| + | ===[[Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL)]]=== | ||
| + | # Flynn J, Jones J, Johnson AJ, Andritsos L, Maddocks K, Jaglowski S, Hessler J, Grever MR, Im E, Zhou H, Zhu Y, Zhang D, Small K, Bannerji R, Byrd JC. Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia. Leukemia. 2015 Feb 24. [Epub ahead of print] [http://www.nature.com/leu/journal/v29/n7/full/leu201531a.html link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/25708835 PubMed] | ||
===[[Multiple myeloma]]=== | ===[[Multiple myeloma]]=== | ||
Revision as of 16:13, 8 July 2015
Mechanism of action
A cyclin dependent kinase inhibitor that selectively inhibits cyclin dependent kinases CDK1, CDK2, CDK5, and CDK9.
Preliminary data
Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL)
- Flynn J, Jones J, Johnson AJ, Andritsos L, Maddocks K, Jaglowski S, Hessler J, Grever MR, Im E, Zhou H, Zhu Y, Zhang D, Small K, Bannerji R, Byrd JC. Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia. Leukemia. 2015 Feb 24. [Epub ahead of print] link to original article PubMed
Multiple myeloma
- Kumar SK, LaPlant B, Chng WJ, Zonder J, Callander N, Fonseca R, Fruth B, Roy V, Erlichman C, Stewart AK. Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single agent activity in patients with relapsed multiple myeloma. Blood. 2014 Nov 13. [Epub ahead of print] link to original article PubMed